BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Finsterer J. Barth syndrome: mechanisms and management. Appl Clin Genet 2019;12:95-106. [PMID: 31239752 DOI: 10.2147/TACG.S171481] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Ren M, Miller PC, Schlame M, Phoon CKL. A critical appraisal of the tafazzin knockdown mouse model of Barth syndrome: what have we learned about pathogenesis and potential treatments? Am J Physiol Heart Circ Physiol 2019;317:H1183-93. [PMID: 31603701 DOI: 10.1152/ajpheart.00504.2019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
2 Cole LK, Agarwal P, Doucette CA, Fonseca M, Xiang B, Sparagna GC, Seshadri N, Vandel M, Dolinsky VW, Hatch GM. Tafazzin Deficiency Reduces Basal Insulin Secretion and Mitochondrial Function in Pancreatic Islets From Male Mice. Endocrinology 2021;162:bqab102. [PMID: 34019639 DOI: 10.1210/endocr/bqab102] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Gerecke BJ, Engberding R. Noncompaction Cardiomyopathy-History and Current Knowledge for Clinical Practice. J Clin Med 2021;10:2457. [PMID: 34206037 DOI: 10.3390/jcm10112457] [Reference Citation Analysis]
4 Simeon M, Dangwal S, Sachinidis A, Doss MX. Application of the Pluripotent Stem Cells and Genomics in Cardiovascular Research-What We Have Learnt and Not Learnt until Now. Cells 2021;10:3112. [PMID: 34831333 DOI: 10.3390/cells10113112] [Reference Citation Analysis]
5 Jones DE, Perez L, Ryan RO. 3-Methylglutaric acid in energy metabolism. Clin Chim Acta 2020;502:233-9. [PMID: 31730811 DOI: 10.1016/j.cca.2019.11.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
6 Almannai M, Salah A, El-Hattab AW. Mitochondrial Membranes and Mitochondrial Genome: Interactions and Clinical Syndromes. Membranes (Basel) 2022;12:625. [PMID: 35736332 DOI: 10.3390/membranes12060625] [Reference Citation Analysis]
7 Sabbah HN. Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid. Heart Fail Rev 2021. [PMID: 34623544 DOI: 10.1007/s10741-021-10177-8] [Reference Citation Analysis]
8 Zegallai HM, Hatch GM. Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets. Mol Cell Biochem 2021;476:1605-29. [PMID: 33415565 DOI: 10.1007/s11010-020-04021-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]